U.S. BioDefense Submits Application to Roche to License and Manufacture TAMIFLU(R)

TAMIFLU(R) is Considered the First Line of Defense Against the H5N1 Avian Flu

Virus That Some Fear Could Spark a Catastrophic Pandemic if it Mutates to

Allow Human-to-Human Transmission



Nov 29, 2005, 00:00 ET from U.S. BioDefense, Inc.

    CITY OF INDUSTRY, Calif., Nov. 29 /PRNewswire-FirstCall/ -- U.S.
 BioDefense, Inc. (OTC Bulletin Board:   UBDE) is pleased to announce today that
 it has met the deadline and submitted an RFQ to Roche Holding in response to
 the need for greater TAMIFLU(R) production.  After receipt of the application
 and review of the information, U.S. BioDefense, Inc. will be informed by Roche
 of the outcome of the evaluation process and the next steps.
     Governments are scrambling to buy vaccines, but production is limited.
 Under pressure from generic-drug companies, developing nations, and the United
 States, Roche agreed late October to discuss granting licenses to others to
 make versions of TAMIFLU(R), which was originally developed by Gilead
 Sciences.  Sales of the drug doubled in the third quarter to about $211
 million.
     According to Dr. Cyndi Chen, Director of Research at U.S. BioDefense,
 "TAMIFLU(R) is considered by many as the first line of defense against the
 H5N1 avian flu virus.  This virus is of great concern as it could spark an
 influenza pandemic human-to-human transmission occurs.  The drug currently can
 reduce the severity of influenza and may slow the transmission between
 humans."
     CEO David Chin stated, "We are hopeful that we will be able to accelerate
 our involvement with strategic vaccination efforts world wide and further
 update our shareholders accordingly.  Due to the increased demand for
 TAMIFLU(R) and increased concerns over potential influenza pandemic, Roche
 (the makers of TAMIFLU(R)) has decided to look for parties interested in toll
 manufacturing of dosage forms or oseltamivir API (active pharmaceutical
 ingredient) for Roche's antiviral drug TAMIFLU(R).  The interested parties
 will help fulfill the demands from the United States and other countries
 world-wide."
     Meanwhile, Chiron, the Emeryville-based maker of the Fluvirin influenza
 shot, won a $62.5 million contract to provide an experimental vaccine for the
 U.S. government's preparations against avian flu.  Health and Human Services
 Secretary Mike Leavitt said the deal is one of a least five in the United
 States has awarded to bolster medical defense against H5N1, the virus that has
 killed at least 62 people in Asia.
 
     Forward-Looking Statements
     Included in this release are certain "forward-looking" statements,
 involving risks and uncertainties, which are covered by the safe harbor
 provisions of the Private Securities Litigation Reform Act of 1995, including
 statements regarding the U.S. BioDefense's financial performance.  Such
 statements are based on management's current expectations and are subject to
 certain factors, risks and uncertainties that may cause actual results, events
 and performance to differ materially from those referred to or implied by such
 statements.  In addition, actual future results may differ materially from
 those anticipated, depending on a variety of factors, including continued
 maintenance of favorable license arrangements, success of market research
 identifying new product opportunities, successful introduction of new
 products, continued product innovation, the success of enhancements to the
 U.S. BioDefense's brand image, sales and earnings growth, ability to attract
 and retain key personnel, and general economic conditions affecting consumer
 spending, including uncertainties relating to global political conditions,
 such as terrorism.  Information with respect to important factors that should
 be considered is contained in the U.S. BioDefense's Annual Report on Form 10-K
 as filed with the Securities and Exchange Commission.  Readers are cautioned
 not to place undue reliance on these forward-looking statements, which speak
 only as of the date hereof.  The U.S. BioDefense does not intend to update any
 of the forward-looking statements after the date of this release to conform
 these statements to actual results or to changes in its expectations, except
 as may be required by law.
 
      Contact:
      U.S. BioDefense, Inc.
      David Chin
      626-961-0562
      info@usbiodefense.com
 
 

SOURCE U.S. BioDefense, Inc.